The use of polyphenols extracted from Chinese sweet leaf tea (Rubus suavissimus S. Lee.) as novel drugs for the treatment of metabolic dysfunction associated steatotic liver disease

利用从中国甜叶茶(Rubus suavissimus S. Lee.)中提取的多酚作为治疗代谢功能障碍相关脂肪肝疾病的新型药物

阅读:1

Abstract

BACKGROUND: Metabolic dysfunction associated steatotic liver disease (MASLD) is a pressing global health issue with limited treatment options. Chinese sweet leaf tea (CSLT), rich in polyphenols, shows promise in addressing MASLD due to its anti-inflammatory, obesity-reducing, and metabolic-regulating properties. This study aimed to explore the therapeutic potential of CSLT polyphenols for MASLD treatment. METHODS: A comprehensive approach combining bioinformatics, network pharmacology, molecular docking, high-throughput sequencing, and experimental validation was employed. CSLT extracts were screened for active compounds, and potential targets associated with MASLD were predicted. A protein-protein interaction network was constructed to identify key regulators of lipid metabolism. Molecular docking studies validated interactions between core polyphenols and MASLD-related targets. In vitro studies using HepG2 cells and in vivo studies in a high-fat diet-induced rat model were conducted to assess the efficacy of polyphenol-rich CSLT extract (PE-CSLT) in ameliorating MASLD symptoms. RESULTS: A total of Eighty-two chemical constituents were initially identified in CSLT. Twenty-six active compounds were screened in CSLT extracts, targeting one hundred and six proteins related to twenty MASLD-associated genes. PE-CSLT demonstrated significant efficacy in reducing body weight gain, serum lipid levels, and liver fat accumulation in MASLD rats. Gene expression analysis revealed modulation of key metabolic regulators, including SREBP1, ACACA, AMPK, and PPARα. Molecular docking confirmed strong binding of eleven PE-CSLT components to these targets. Our findings highlight the therapeutic potential of PE-CSLT for MASLD, providing a scientific basis for its development as a novel drug. CONCLUSION: This study underscores the promise of natural products in modern medicinal practices and emphasizes the need for further clinical evaluation of PE-CSLT in MASLD management. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41065-025-00504-6.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。